Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
~150000 g/mol
Drug class
Recombinant human arginase 1 enzyme replacement therapyarginine-depleting biologic
Mechanism of action
Provides exogenous arginase 1 activity, converting excess arginine to urea and ornithine and thereby lowering plasma arginine in patients with arginase 1 deficiency.
Indications / reported uses
Treatment of hyperargininaemia in adults and paediatric patients aged 2 years and older with arginase 1 deficiency, in conjunction with dietary protein restriction, under the current product label.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Pegzilarginase Environmental Risk Assessment (ERA) (the Pegzilarginase ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.